Nidogen-1 is a Novel Extracellular Ligand for the NKp44 Activating Receptor

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2018 Sep 20

PMID 30228939

Citations 47

Authors

Silvia Gaggero

Maurizio Bruschi

Andrea Petretto

Monica Parodi

Genny Del Zotto

Chiara Lavarello

Carola Prato

Laura Santucci

Alessandra Barbuto

Cristina Bottino

Giovanni Candiano

Alessandro Moretta

Massimo Vitale

Lorenzo Moretta

Claudia Cantoni

Affiliations

Soon will be listed here.

Abstract

The release of soluble ligands of activating Natural Killer (NK) cell receptors may represent a regulatory mechanism of NK cell function both in physiologic and in pathologic conditions. Here, we identified the extracellular matrix protein Nidogen-1 (NID1) as a ligand of NKp44, an important activating receptor expressed by activated NK cells. When released as soluble molecule, NID1 regulates NK cell function by modulating NKp44-induced IFN-γ production or cytotoxicity. In particular, it also modulates IFN-γ production induced by Platelet-Derived Growth Factor (PDGF)-DD following NKp44 engagement. We also show that NID1 may be present at the cell surface. In this form or when bound to a solid support (bNID1), NID1 fails to induce NK cell cytotoxicity or cytokine release. However, analysis by mass spectrometry revealed that exposure to bNID1 can induce in human NK cells relevant changes in the proteomic profiles suggesting an effect on different biological processes.

Citing Articles

Recognition of Self and Viral Ligands by NK Cell Receptors.

Mariuzza R, Singh P, Karade S, Shahid S, Sharma V Immunol Rev. 2025; 329(1):e13435.

PMID: 39748148 PMC: 11695704. DOI: 10.1111/imr.13435.

Germline natural killer cell receptors modulating the T cell response.

Mora-Bitria L, Asquith B Front Immunol. 2024; 15:1477991.

PMID: 39559364 PMC: 11570266. DOI: 10.3389/fimmu.2024.1477991.

Claudin2 is involved in the interaction between Megalocytivirus-induced virus-mock basement membrane (VMBM) and lymphatic endothelial cells.

He J, Han D, Meng X, Li L, Hu B, Yan M Vet Res. 2024; 55(1):143.

PMID: 39506812 PMC: 11542248. DOI: 10.1186/s13567-024-01404-9.

Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy.

Douka S, Papamoschou V, Raimo M, Mastrobattista E, Caiazzo M Pharmaceutics. 2024; 16(9).

PMID: 39339180 PMC: 11434712. DOI: 10.3390/pharmaceutics16091143.

Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma.

Dong S, Zhao M, Zhu J, Li T, Yan M, Xing K Front Immunol. 2024; 15:1442673.

PMID: 39234249 PMC: 11371580. DOI: 10.3389/fimmu.2024.1442673.

References

Aleckovic M, Wei Y, LeRoy G, Sidoli S, Liu D, Garcia B . Identification of Nidogen 1 as a lung metastasis protein through secretome analysis. Genes Dev. 2017; 31(14):1439-1455. PMC: 5588926. DOI: 10.1101/gad.301937.117. View

Horton N, Mathew S, Mathew P . Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44. PLoS One. 2013; 8(3):e59552. PMC: 3602199. DOI: 10.1371/journal.pone.0059552. View

Thoren F, Riise R, Ousback J, Della Chiesa M, Alsterholm M, Marcenaro E . Human NK Cells induce neutrophil apoptosis via an NKp46- and Fas-dependent mechanism. J Immunol. 2012; 188(4):1668-74. DOI: 10.4049/jimmunol.1102002. View

Narni-Mancinelli E, Gauthier L, Baratin M, Guia S, Fenis A, Deghmane A . Complement factor P is a ligand for the natural killer cell-activating receptor NKp46. Sci Immunol. 2017; 2(10). PMC: 5419422. DOI: 10.1126/sciimmunol.aam9628. View

Bruschi M, Musante L, Candiano G, Ghiggeri G, Herbert B, Antonucci F . Soft immobilized pH gradient gels in proteome analysis: a follow-up. Proteomics. 2003; 3(6):821-5. DOI: 10.1002/pmic.200300361. View

Vizcaino J, Csordas A, Del-Toro N, Dianes J, Griss J, Lavidas I . 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2015; 44(D1):D447-56. PMC: 4702828. DOI: 10.1093/nar/gkv1145. View

Brandt C, Baratin M, Yi E, Kennedy J, Gao Z, Fox B . The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009; 206(7):1495-503. PMC: 2715080. DOI: 10.1084/jem.20090681. View

Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P . Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. Cancer Res. 2016; 76(8):2153-65. DOI: 10.1158/0008-5472.CAN-15-1965. View

El-Gazzar A, Groh V, Spies T . Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol. 2013; 191(4):1509-15. PMC: 3736343. DOI: 10.4049/jimmunol.1301071. View

10.

Wang W, Guo H, Geng J, Zheng X, Wei H, Sun R . Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack. J Biol Chem. 2014; 289(48):33311-9. PMC: 4246088. DOI: 10.1074/jbc.M114.603464. View

11.

Barrow A, Edeling M, Trifonov V, Luo J, Goyal P, Bohl B . Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor. Cell. 2017; 172(3):534-548.e19. PMC: 6684025. DOI: 10.1016/j.cell.2017.11.037. View

12.

Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debre P, Vieillard V . Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood. 2013; 122(17):2935-42. DOI: 10.1182/blood-2013-03-489054. View

13.

Knorr D, Bachanova V, Verneris M, Miller J . Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol. 2014; 26(2):161-72. PMC: 3984606. DOI: 10.1016/j.smim.2014.02.002. View

14.

Baury B, Masson D, McDermott Jr B, Jarry A, Blottiere H, Blanchardie P . Identification of secreted CD155 isoforms. Biochem Biophys Res Commun. 2003; 309(1):175-82. DOI: 10.1016/s0006-291x(03)01560-2. View

15.

Alsultan A, Shamseldin H, Osman M, Aljabri M, Alkuraya F . MYSM1 is mutated in a family with transient transfusion-dependent anemia, mild thrombocytopenia, and low NK- and B-cell counts. Blood. 2013; 122(23):3844-5. DOI: 10.1182/blood-2013-09-527127. View

16.

Montaldo E, Vacca P, Moretta L, Mingari M . Development of human natural killer cells and other innate lymphoid cells. Semin Immunol. 2014; 26(2):107-13. DOI: 10.1016/j.smim.2014.01.006. View

17.

Brusilovsky M, Radinsky O, Cohen L, Yossef R, Shemesh A, Braiman A . Regulation of natural cytotoxicity receptors by heparan sulfate proteoglycans in -cis: A lesson from NKp44. Eur J Immunol. 2014; 45(4):1180-91. PMC: 4415513. DOI: 10.1002/eji.201445177. View

18.

Shibuya A, Campbell D, Hannum C, Yssel H, McClanahan T, Kitamura T . DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996; 4(6):573-81. DOI: 10.1016/s1074-7613(00)70060-4. View

19.

Lanier L . NKG2D Receptor and Its Ligands in Host Defense. Cancer Immunol Res. 2015; 3(6):575-82. PMC: 4457299. DOI: 10.1158/2326-6066.CIR-15-0098. View

20.

Martino-Echarri E, Fernandez-Rodriguez R, Rodriguez-Baena F, Barrientos-Duran A, Torres-Collado A, Plaza-Calonge M . Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2. Int J Cancer. 2013; 133(10):2315-24. DOI: 10.1002/ijc.28271. View